Compound name
C3TD879
Protein family
Protein Kinase
Target name
CIT
Affinity biochemical (nM)
12
Affinity on-target cellular (nM)
0.3
CG-Set
Kinase set
Recommended Concentration
2 µM
Compound EUbOPEN ID
EUB0003024a
SMILES
Cc1cc(ccc1c1ccnc2c1cc(C)[nH]2)NC([C@@H](CC(C)(C)C)N)=O
InChIKey
ODOJVROSIRINJT-LJQANCHMSA-N
NCBI gene ID
11113
UniProt ID
O14578
Synonyms
KIAA0949, STK21, CRIK, CITK
Mode of action
Inhibitor
Negative control
C3TD879
Affinity biochemical definition
IC50
Affinity biochemical assay type
LANCE TR-FRET assay (using 10 µM ATP)
Affinity Biochemical Source Knowledge
https://pubmed.ncbi.nlm.nih.gov/38330278/
Affinity biochemical relation
=
Affinity on-target cellular definition
Kd
Affinity on-target cellular assay type
NanoBRET Assay (NanoLuc, inhibition of kinase domain, using HEK293T cells)
Affinity on-target cellular source knowledge
https://pubmed.ncbi.nlm.nih.gov/38330278/
Affinity on-target cellular relation
=
Selectivity platform
Eurofins KinaseProfiler assay
Selectivity platform number of targets
373
Selectivity remarks
Screened at 1 µM, closest targets as % of control: AAK1 (13%), MNK2 (35%), ACK1 (39%), BIKE (50%), full screening data are available as supporting information;
In-vitro potency (enzymatic assay): IC50(AAK1) = 212 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(BIKE) = 902 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(MNK2) = 2180 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(HIPK4) = 2275 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(ACK1) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(DRAK2) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AAK1) = 6.2 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(BMP2K) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(MKNK2) = 5.5 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(HIPK4) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(STK17B) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKB) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(GAK) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(PRKACA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (enzymatic assay): IC50(AAK1) = 212 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(BIKE) = 902 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(MNK2) = 2180 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(HIPK4) = 2275 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(ACK1) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (enzymatic assay): IC50(DRAK2) >3000 nM, https://pubmed.ncbi.nlm.nih.gov/38330278/;
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AAK1) = 6.2 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(BMP2K) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(MKNK2) = 5.5 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(HIPK4) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(STK17B) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(AURKB) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(GAK) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
In-vitro potency (NanoBRET assay, HEK293T cells): IC50(PRKACA) >10 µM, https://www.sgc-ffm.uni-frankfurt.de/#!detailedpotencydataview/C3TD879
Selectivity Source Knowledge
https://pubmed.ncbi.nlm.nih.gov/38330278/
Selectivity Number of Off-targets
2